Quote · Bloomberg Intelligence
Carnival Leads Cruise Stocks Lower on Weak 3Q Outlook
Where this was said
Dave Ricks' Speed Strategy & Tirzepatide's 5-Year Timeline
At 28:57 · chapter starts 28:38
Madison Muller details how CEO Dave Ricks made speed Eli Lilly's number-one priority, cutting drug development from 13–14 years to 5, and piloted this approach with tirzepatide. [1] — Madison Muller "When Dave Ricks took over as CEO, Eli Lilly was one of the slowest drug developers in the industry. He mandated speed above all else. The r…" 28:38
When Dave Ricks took over as CEO, Eli Lilly was one of the slowest drug developers in the industry. He mandated speed above all else. The result: tirzepatide went from lab to approval in about 5 years — less than half the old timeline.
Under CEO Dave Ricks, Eli Lilly cut drug development timelines from 13–14 years to around 5 years, exemplified by the speedy development of tirzepatide (Mounjaro/Zepbound).
Eli Lilly is deploying its GLP-1 windfall into internal R&D, acquisitions, and AI — including a partnership with NVIDIA and an on-site supercomputer. The question is whether AI can actually deliver new drugs before Lilly's patents expire.
